Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Beckman · SciRah

Researcher profile · Semantic Scholar

R. Beckman

Share profile

R. Beckman — researcher profile on SciRah

h-index: 38
Works: 162
Citations: 4,646

Most-cited papers

A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)
M. Ghadessi, R. Tang, Joey Tianyi Zhou, Rong Liu +6 more
2020Orphanet Journal of Rare Diseases156 citations Open access
Semantic Scholar
A roadmap to using randomization in clinical trials
V. Berger, L. Bour, Kerstine Carter, J. Chipman +10 more
2021BMC Medical Research Methodology120 citations Open access
Semantic Scholar
Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation
Eric A. Stahlberg, M. Abdel-Rahman, Boris Aguilar, A. Asadpoure +29 more
2022Frontiers in Digital Health117 citations Open access
Semantic Scholar
Integrating predictive biomarkers and classifiers into oncology clinical development programs
R. Beckman
201492 citations
Semantic Scholar
Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
P. LoRusso, P. Jänne, M. Oliveira, N. Rizvi +11 more
2013Clinical Cancer Research91 citations Open access
Semantic Scholar
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer
A. Forero-Torres, J. Infante, D. Waterhouse, L. Wong +14 more
2013Cancer Medicine87 citations Open access
Semantic Scholar
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers
T. Yap, Li Yan, A. Patnaik, N. Tunariu +19 more
2014Clinical Cancer Research80 citations Open access
Semantic Scholar
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
A. Cheng, Yoon-Koo Kang, A. He, H. Lim +10 more
2015Journal of Hepatology54 citations
Semantic Scholar
Extensive subclonal mutational diversity in human colorectal cancer and its significance
L. Loeb, Brendan F. Kohrn, Kaitlyn J. Loubet-Senear, Yasmin J. Dunn +5 more
2019Proceedings of the National Academy of Sciences of the United States of America53 citations Open access
Semantic Scholar
Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study
Cong Chen, Xiao-Yun Li, S. Yuan, Z. Antonijevic +2 more
201653 citations
Semantic Scholar
Optimized adaptive enrichment designs
Thomas Ondra, Sebastian Jobjornsson, R. Beckman, C. Burman +3 more
2017Statistical Methods in Medical Research45 citations Open access
Semantic Scholar
A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
M. Reck, M. Krzakowski, E. Chmielowska, M. Sebastian +6 more
2013Lung Cancer43 citations
Semantic Scholar
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
J. Mendell, D. Freeman, Wenqin Feng, T. Hettmann +10 more
2015EBioMedicine42 citations Open access
Semantic Scholar
Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.
M. Ciprotti, N. Tebbutt, F. Lee, Sze T. Lee +18 more
2015Journal of Clinical Oncology41 citations Open access
Semantic Scholar
Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective
M. Ghadessi, Jun-Rui Di, Chenkun Wang, Kiichiro Toyoizumi +6 more
2023Orphanet Journal of Rare Diseases38 citations Open access
Semantic Scholar
How Should Cancer Models Be Constructed?
R. Beckman, I. Kareva, F. Adler
2020Cancer Control: Journal of the Moffitt Cancer Cente31 citations Open access
Semantic Scholar
Optimizing Trial Designs for Targeted Therapies
Thomas Ondra, Sebastian Jobjornsson, R. Beckman, C. Burman +3 more
2016PLoS ONE27 citations Open access
Semantic Scholar
Rare Mutations in Cancer Drug Resistance and Implications for Therapy
R. Beckman, L. Loeb
2020Clinical pharmacology and therapy24 citations Open access
Semantic Scholar
Modelling bistable tumour population dynamics to design effective treatment strategies
Andrei R. Akhmetzhanov, J. W. Kim, Ryan Sullivan, R. Beckman +2 more
2018bioRxiv24 citations Open access
Semantic Scholar
Envisioning the future of precision oncology trials
S. Madhavan, R. Beckman, M. McCoy, M. Pishvaian +2 more
2021Nature Cancer23 citations
Semantic Scholar
Molecular Simulation of Receptor Occupancy and Tumor Penetration of an Antibody and Smaller Scaffolds: Application to Molecular Imaging
K. Orcutt, G. Adams, Anna M. Wu, Matthew D. Silva +7 more
2017Molecular Imaging and Biology23 citations
Semantic Scholar
Evolutionary Dynamics and Significance of Multiple Subclonal Mutations in Cancer
R. Beckman, L. Loeb
2017DNA Repair23 citations Open access
Semantic Scholar
Adaptive Informational Design of Confirmatory Phase III Trials With an Uncertain Biomarker Effect to Improve the Probability of Success
Cong Chen, Nicole F. Li, Shen-Tu Yue, Lei Pang +1 more
201623 citations
Semantic Scholar
Platform Trial Designs in Drug Development
Z. Antonijevic, R. Beckman
201820 citations
Semantic Scholar
Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment
Shruti Rao, R. Beckman, S. Riazi, Cinthya S Yabar +5 more
2016OncoTarget20 citations Open access
Semantic Scholar
Long range personalized cancer treatment strategies incorporating evolutionary dynamics
Chen-Hsiang Yeang, R. Beckman
2016Biology Direct19 citations Open access
Semantic Scholar
Maximizing Return on Socioeconomic Investment in Phase II Proof-of-Concept Trials
Cong Chen, R. Beckman
2014Clinical Cancer Research19 citations
Semantic Scholar
Molecular Imaging of Death Receptor 5 Occupancy and Saturation Kinetics In Vivo by Humanized Monoclonal Antibody CS-1008
I. Burvenich, F. Lee, Glenn A. Cartwright, G. O'Keefe +10 more
2013Clinical Cancer Research19 citations
Semantic Scholar
Design and Execution of Sustainable Decentralized Clinical Trials
Pritibha Singh, Andrea Burden, F. Natanegara, R. Beckman
2023Clinical pharmacology and therapy18 citations Open access
Semantic Scholar
Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs)
J. von Pawel, Jennifer F. Tseng, M. Dediu, C. Schumann +6 more
201517 citations
Semantic Scholar
Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study
M. Dillon, L. Grove, K. Newbold, H. Shaw +9 more
2018Clinical Cancer Research16 citations Open access
Semantic Scholar
Advancing innovative clinical trials to efficiently deliver medicines to patients
R. Beckman, F. Natanegara, Pritibha Singh, Freda Cooner +9 more
2022Nature reviews. Drug discovery14 citations Open access
Semantic Scholar
Adaptive expansion of biomarker populations in phase 3 clinical trials.
Cong Chen, Xiao-Yun Li, Wen Li, R. Beckman
2018Contemporary Clinical Trials14 citations
Semantic Scholar
Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs).
J. von Pawel, Jennifer F. Tseng, M. Dediu, C. Schumann +6 more
201414 citations
Semantic Scholar
How many tumor indications should be initially screened in development of next generation immunotherapies?
Cong Chen, Q. Deng, Linchen He, D. Mehrotra +2 more
2017Contemporary Clinical Trials13 citations
Semantic Scholar
Efficiency of a randomized confirmatory basket trial design constrained to control the family wise error rate by indication
Lin-Chen He, Yuru Ren, Han Chen, Daphne Guinn +5 more
2022Statistical Methods in Medical Research11 citations Open access
Semantic Scholar
Combining 3D modeling with artificial intelligence to increase specificity and precision in peptide:MHC binding predictions
Michelle P. Aranha, Yead S. M. Jewel, R. Beckman, L. Weiner +3 more
2020Journal of Immunology11 citations Open access
Semantic Scholar
Estimation of treatment effect in two‐stage confirmatory oncology trials of personalized medicines
Wen Li, Cong Chen, Xiao-Yun Li, R. Beckman
2017Statistics in Medicine11 citations
Semantic Scholar
Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development.
R. Beckman, Cong Chen
2015Advances in Experimental Medicine and Biology9 citations
Semantic Scholar
Adaptive Endpoints Selection with Application in Rare Disease
Heng Xu, Yi Liu, R. Beckman
2023Statistics in Biopharmaceutical Research8 citations
Semantic Scholar
Impact of COVID-19 pandemic on oncology clinical trial design, data collection and analysis
R. Tang, Jian Zhu, Tai-Tsang Chen, Fang Liu +4 more
2022Contemporary Clinical Trials8 citations Open access
Semantic Scholar
A framework for assessing the impact of accelerated approval
A. Gould, R. Campbell, J. Loewy, R. Beckman +7 more
2022medRxiv8 citations Open access
Semantic Scholar
Planning for the Next Pandemic: Ethics and Innovation Today for Improved Clinical Trials Tomorrow
Gianna McMillan, Cristiana Mayer, R. Tang, Yi Liu +3 more
2021Statistics in Biopharmaceutical Research8 citations Open access
Semantic Scholar
Multi‐stage enrichment and basket trial designs with population selection
Wen Li, Jing Zhao, Xiao-Yun Li, Cong Chen +1 more
2019Statistics in Medicine8 citations
Semantic Scholar
High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia
Frances Linzee Mabrey, S. Chien, Timothy S. Martins, J. Annis +15 more
2018Blood8 citations
Semantic Scholar
On Group Sequential Enrichment Design for Basket Trial
S. Yuan, A. Chen, Li He, Cong Chen +2 more
20167 citations
Semantic Scholar
Nonstandard personalized medicine strategies for cancer may lead to improved patient outcomes.
R. Beckman, Chen-Hsiang Yeang
2014Personalized Medicine7 citations
Semantic Scholar
Eye-Tracking Study to Enhance Usability of Molecular Diagnostics Reports in Cancer Precision Medicine.
Vishakha Sharma, Allan Fong, R. Beckman, Shruti Rao +4 more
2018JCO Precision Oncology6 citations Open access
Semantic Scholar
Pharmacokinetics, safety, and tolerability of a new patritumab formulation in patients with advanced, refractory solid tumors.
K. Papadopoulos, K. Moore, R. Lush, Madhuri Desai +3 more
20156 citations
Semantic Scholar
Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
S. Bahnassy, Hillary Stires, Lu Jin, Stanley Tam +6 more
2023bioRxiv5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Cong Chen×8
Invite
Cong Chen — researcher profile on SciRah
R. Tang×6
Invite
R. Tang — researcher profile on SciRah
J. Greenberg×6
Invite
J. Greenberg — researcher profile on SciRah
Z. Antonijevic×5
Invite
Z. Antonijevic — researcher profile on SciRah

×4

Invite

S. Madhavan — researcher profile on SciRah

C. Copigneaux×4

Invite

C. Copigneaux — researcher profile on SciRah

Invite

L. Loeb — researcher profile on SciRah

Invite

Xiao-Yun Li — researcher profile on SciRah

J. von Pawel×4

Invite

J. von Pawel — researcher profile on SciRah

Invite

M. McCoy — researcher profile on SciRah

Xiao-Ping Jin×3

Invite

Xiao-Ping Jin — researcher profile on SciRah

Invite

Qiang Wang — researcher profile on SciRah